Who are Methotrexate alone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Placebo Methotrexate, MTX therapy, Methotrexate therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/methotrexate-alone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Methotrexate alone — Competitive Intelligence Brief

Methotrexate alone (Methotrexate alone) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Folate antagonist / Antimetabolite. Area: Oncology, Immunology, Rheumatology.

phase 3 Folate antagonist / Antimetabolite Dihydrofolate reductase (DHFR) Oncology, Immunology, Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Methotrexate alone (Methotrexate alone) — Helsinki University Central Hospital. Methotrexate inhibits dihydrofolate reductase, blocking folate metabolism and reducing DNA synthesis and cell proliferation.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Methotrexate alone TARGET	Methotrexate alone	Helsinki University Central Hospital	phase 3	Folate antagonist / Antimetabolite	Dihydrofolate reductase (DHFR)
Placebo Methotrexate	Placebo Methotrexate	AbbVie	marketed	Folate antagonist / Antimetabolite	Dihydrofolate reductase (DHFR)
MTX therapy	MTX therapy	NYU Langone Health	marketed	Folate antagonist / Antimetabolite	Dihydrofolate reductase (DHFR)
Methotrexate therapy	Methotrexate therapy	National Medical Research Center for Children's Health, Russian Federation	marketed	Folate antagonist / Antimetabolite	Dihydrofolate reductase (DHFR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Folate antagonist / Antimetabolite class)

AbbVie · 1 drug in this class
Helsinki University Central Hospital · 1 drug in this class
NYU Langone Health · 1 drug in this class
National Medical Research Center for Children's Health, Russian Federation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Methotrexate alone — Competitive Intelligence Brief. https://druglandscape.com/ci/methotrexate-alone. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab